A collaboration shaping the development and manufacturing path for in vivo lentiviral vectors (LVV)
Connecting cell line innovation, process development and manufacturing expertise to build the next generation of in vivo LVV programs
In vivo LVV therapies introduce new development and manufacturing challenges. Developers must balance transgene design, vector performance, manufacturability, scalability and regulatory expectations from the earliest stages of development.
Lonza and Asimov bring together complementary capabilities spanning genetic design technologies, advanced cell line technologies, process development, analytics and GMP manufacturing readiness. Together we connect upstream innovation with scalable development and manufacturing to accelerate the path from concept to clinic.
Complementary expertise.
One development path.
Advanced design and engineering technologies
- Genetic system design and optimization
- High-performance lentiviral packaging and producer cell line technologies
- Cell line engineering capabilities and technologies supporting ex vivo and in vivo applications
- Computational and design-driven approaches for advanced therapies
Development and manufacturing expertise
- Process and analytical development
- Scale-up and technology transfer GMP manufacturing
- Regulatory and CMC support
- Global quality systems and commercial manufacturing experience
Designed for emerging in vivo applications
The transition from ex vivo to in vivo applications is driving new manufacturing requirements for lentiviral vectors.
Developers must navigate
- Manufacturability and scalability
- Product quality and analytical characterization
- Regulatory and CMC expectations
- Balancing vector performance with commercial feasibility
By combining cell line technologies with manufacturing expertise, Lonza and Asimov help developers address these challenges earlier in development.
Bringing manufacturability into development earlier
In vivo lentiviral therapies introduce a new level of complexity for developers. Design decisions made early in development can have significant implications for product quality, scalability and long-term manufacturing success.
Through this collaboration, biological design and manufacturing considerations can be connected earlier, helping developers create more manufacturable and scalable solutions from the outset.
Expanding expertise across the product lifecycle
Fully integrated approach to support developers considering manufacturability earlier and streamline the transition from development to manufacturing
Where could your in vivo LVV program go next?
Whether you are evaluating cell line technologies or broader manufacturing strategies, Lonza’s team can help evaluate how the combined capabilities may support your program.
Talk to our team about your in vivo LVV program and learn how we can support your development and manufacturing strategy.
